478963-46-1 Usage
Uses
Used in Pharmaceutical Industry:
2(1H)-Quinazolinone, 1-(1-methylethyl)-4-[4-(1-methylethyl)phenyl]-6-(2-propyn-1-ylamino)is used as a potential pharmaceutical agent for its bioactive properties. The quinazolinone core and specific substituents on this compound may contribute to its pharmacological activity, making it a valuable molecule for drug development and research.
Used in Drug Development:
2(1H)-QUINAZOLINONE, 1-(1-METHYLETHYL)-4-[4-(1-METHYLETHYL)PHENYL]-6-(2-PROPYN-1-YLAMINO)is utilized in drug development due to its potential pharmaceutical properties. The quinazolinone derivatives are known for their bioactive effects, and the specific substituents in this compound may enhance its pharmacological activity, making it a promising candidate for the development of new drugs with therapeutic applications.
Used in Research:
2(1H)-Quinazolinone, 1-(1-methylethyl)-4-[4-(1-methylethyl)phenyl]-6-(2-propyn-1-ylamino)is employed in research to explore its potential applications in various fields, such as medicinal chemistry, pharmacology, and drug discovery. The unique chemical structure and bioactive properties of this compound make it an interesting subject for further investigation and understanding of its potential therapeutic effects.
Check Digit Verification of cas no
The CAS Registry Mumber 478963-46-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,7,8,9,6 and 3 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 478963-46:
(8*4)+(7*7)+(6*8)+(5*9)+(4*6)+(3*3)+(2*4)+(1*6)=221
221 % 10 = 1
So 478963-46-1 is a valid CAS Registry Number.
InChI:InChI=1/C23H25N3O/c1-6-13-24-19-11-12-21-20(14-19)22(25-23(27)26(21)16(4)5)18-9-7-17(8-10-18)15(2)3/h1,7-12,14-16,24H,13H2,2-5H3
478963-46-1Relevant articles and documents
L-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: A novel series of potent calcium-sensing receptor antagonists
Widler, Leo,Altmann, Eva,Beerli, René,Breitenstein, Werner,Bouhelal, Rochdi,Buhl, Thomas,Gamse, Rainer,Gerspacher, Marc,Halleux, Christine,John, Markus R.,Lehmann, Hansjoerg,Kalb, Oskar,Kneissel, Michaela,Missbach, Martin,Müller, Irene R.,Reidemeister, Sibylle,Renaud, Johanne,Taillardat, Agnes,Tommasi, Ruben,Weiler, Sven,Wolf, Romain M.,Seuwen, Klaus
scheme or table, p. 2250 - 2263 (2010/08/21)
Parathyroid hormone (PTH) is an effective bone anabolic agent. However, only when administered by daily sc injections exposure of short duration is achieved, a prerequisite for an anabolic response. Instead of applying exogenous PTH, mobilization of endogenous stores of the hormone can be envisaged. The secretion of PTH stored in the parathyroid glands is mediated by a calcium sensing receptor (CaSR) a GPCR localized at the cell surface. Antagonists of CaSR (calcilytics) mimic a state of hypocalcaemia and stimulate PTH release to the bloodstream. Screening of the internal compound collection for inhibition of CaSR signaling function afforded 2a. In vitro potency could be improved > 1000 fold by optimization of its chemical structure. The binding mode of our compounds was predicted based on molecular modeling and confirmed by testing with mutated receptors. While the compounds readily induced PTH release after iv application a special formulation was needed for oral activity. The required profile was achieved by using microemulsions. Excellent PK/PD correlation was found in rats and dogs. High levels of PTH were reached in plasma within minutes which reverted to baseline in about 1-2 h in both species.
